← Back to screener

Emergent BioSolutions Inc. EBS

Rank #1691 · NYSE · $0.4B market cap
⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
44.2
P/E
-0.5
P/B
0.25
ROE
-54.8%
Op. Margin
-69.2%
Debt Ratio
65%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -0.5x, P/B 0.25x. Ranks in the top 50% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -54.8%. Ranks in the top 88% of the universe.

Safety ★★★★☆
Good

Debt ratio 65%. Ranks in the top 28% of the universe.

Growth ★☆☆☆☆
Weak

Revenue decline of 6.1% year over year. Ranks in the top 78% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$0.0B$0.0B$0.4B–34
2012$0.3B$0.1B$0.1B$0.4B25.731
2013$0.3B$0.0B$0.0B$0.4B11.728
2014$0.3B$0.0B$0.0B$0.5B10.628
2015$0.3B$0.0B$0.0B$0.4B13.787
2016–$0.1B$0.0B$0.5B–77
2017–$0.1B$0.1B$0.6B–68
2018$0.5B$0.1B$0.1B$0.7B21.624
2019$0.6B$0.1B$0.1B$0.6B22.2204
2020$0.8B$0.1B$0.1B$0.9B11.5136
2021$1.1B$0.1B$0.1B$1.0B10.3142
2022$1.6B$0.4B$0.3B$1.1B27.9123
2023$1.8B$0.3B$0.2B$1.5B19.2123
2024$1.1B$-0.2B$-0.2B$1.6B-15.273
2025$1.0B$-0.7B$-0.8B$1.4B-69.265

← See the full screener